Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
GHK-Cu was found to activate genes related to tissue regeneration, blood vessel growth, nerve regeneration, and antioxidant defense while suppressing genes associated with inflammation, cancer pathways, and fibrosis
As we move forward in 2026, research in this field continues to accelerate, promising even more refined ways to support tissue adaptation and cellular health
Copper is an essential trace mineral involved in numerous enzymatic reactions, including those governing: collagen crosslinking antioxidant defense connective tissue formation mitochondrial respiration When bound to copper, GHK acts as a carrier molecule that delivers bioavailable copper to cells while simultaneously triggering regenerative signaling pathways
The synergy might arise from the combined action of GHK-Cu in stimulating glycosaminoglycan production, promoting collagen synthesis, and HA's role in reducing collagen degradation by scavenging reactive oxygen species and inhibiting matrix metalloproteinases
So then why doesnt another big pharmaceutical company swoop in, buy the patent, and use their exhaustive funds to get BPC FDA approved, then make billions of dollars selling the drug to an already interested market
